The 5th Medical Device Software Development Summit is your must-attend opportunity to gain actionable strategies, real-world ...

According to Prof Phil Banfield, chair of the BMA council, it had become clear that the centre "no longer has a grip on the ...

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) had been scheduled to meet to discuss the strains ...

Nevertheless, the rise in the Statutory Scheme rate to almost a third of pharma company revenue – which brings the average ...

Jane Chung, president and chief operating officer at Sutro, is replacing Bill Newell as chief executive as the company starts ...

New data from the phase 3 MINT trial in adults living with autoimmune disorder generalised myasthenia gravis (gMG) – which ...

Rumours that Donald Trump had chosen Martin Makary as FDA Commissioner have been confirmed, while the President-Elect has also selected Dave Weldon to lead the Centers for Disease Control and ...

While immunotherapies have transformed treatment of many types of cancer, they do sometimes fail to have an impact – as Merck & Co has just observed in a study of Keytruda in head and neck cancer.

About the author Sarah Rickwood has 30 years’ experience as a consultant to the pharmaceutical industry, having worked in Accenture’s pharmaceutical strategy practice prior to joining IQVIA ...

MSD has started a phase 3 trial of ROR1-directed zilovertamab vedotin (zilo-V) as a treatment for previously untreated diffuse large B-cell lymphoma (DLBCL), cementing the antibody-drug conjugate ...

Bristol-Myers Squibb's Celgene unit has clearly been impressed by progress in its four-year-old alliance with Evotec on protein degradation. It's just paid $200 million to extend the partnership ...